toosendanin has been researched along with Triple Negative Breast Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, L; Lu, B; Mei, X; Wang, Z; Yang, F; Yang, R; Zhang, J | 1 |
| Chen, CH; Chen, Y; Li, D; Liu, Q; Pan, ZH; Shao, LD; Xiao, WW; Zhang, H | 1 |
| Cho, WCS; Lin, ZX; Wu, YL; Xian, YF; Xu, HX; Zhang, J | 1 |
3 other study(ies) available for toosendanin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Female; Humans; Mice, Inbred BALB C; Necrosis; Triple Negative Breast Neoplasms; Triterpenes; Xenograft Model Antitumor Assays | 2022 |
Design, synthesis, and anti-triple negative breast cancer activity of novel Toosendanin derivatives.
Topics: Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; Humans; Triple Negative Breast Neoplasms | 2023 |
Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Topics: Animals; Cell Line, Tumor; Drugs, Chinese Herbal; Epithelial-Mesenchymal Transition; Humans; Mice; Paclitaxel; Triple Negative Breast Neoplasms; Triterpenes | 2023 |